After the Indian Council of Medical Research (ICMR) dropped usage of convalescent plasma from recommended treatment protocol for Covid-19, Ganga Ram hospital Chairperson Dr. DS Rana has said that Remdesivir is also being considered to be dropped from Covid-19 treatment soon.
“If we talk about other medicines which we use in COVID treatment, there is no such evidence regarding Remdesivir that works in COVID-19 treatment. Medicines that do not have any activity to work, will have to be discontinued,” said Dr. Rana.
“All the experimental medicines, be plasma therapy or Remdesivir, all of them may be dropped soon as there is no such evidence of its functioning. Right now only three medicines are working,” Dr. Rana said.
Remdesivir is a patented drug, manufactured in India under voluntary licenses granted by patent holder Gilead Life Sciences US to seven Indian pharmaceutical companies – Cipla, Dr Reddy’s Lab, Hetero, Jubilant Pharma, Mylan, Syngene, and Zydus Cadila.